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Abstract
The mammalian Toll-like receptors (TLRs) are expressed on macrophages and dendritic cells, which are primarily involved
in innate immunity. At present, ligands for several of the TLRs, such as TLR2, TLR3, TLR4, TLR5, TLR6, and TLR9, have
been identified. Most of these ligands are derived from pathogens, but not found in the host, suggesting that the TLRs are
critical to sensing invading microorganisms. Pathogen recognition by TLRs provokes rapid activation of innate immunity by
inducing production of proinflammatory cytokines and upregulation of costimulatory molecules. Activated innate immunity
subsequently leads to effective adaptive immunity. In this regard, the TLRs are considered to be adjuvant receptors. Distinct
TLRs can exert distinct, but overlapping sets of biological effects. Accumulating evidence indicates that this can be attributed
to both the common and unique aspects of the signaling mechanisms that mediate TLR family responses. For example,
TLR2 and TLR9 require MyD88 as an essential signal transducer, whereas TLR4 can induce costimulatory molecule
upregulation in a MyD88-independent manner. Understanding the TLR system should offer invaluable opportunity for
manipulating host immune responses. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Immune responses consist of two major types of
immunity, i.e., innate and adaptive. Adaptive im-
munity, which is mediated by B and T lymphocytes,
can recognize pathogens with high a⁄nity through
rearranged receptors. However, the establishment of
adaptive immunity is typically not rapid enough to
eradicate microorganisms. Therefore, it is the more
rapidly responding innate immunity that plays a ma-
jor role in host defense during the early stages of
infection. Innate immunity recognition of invading
pathogens is mediated by a set of germline-encoded
receptors that have evolved to recognize conserved
molecular patterns shared by large groups of organ-
isms. Recent accumulating evidence has shown that
this recognition can be attributed mainly to the Toll-
like receptor (TLR) family. TLR signaling can in-
duce the production of proin£ammatory cytokines
and upregulate expression of costimulatory mole-
cules, thereby activating not only innate but ulti-
mately also adaptive immunity. In this article, we
describe the critical roles played by the TLR family
in host defense, and the signaling mechanisms that
mediate the response to TLR ligands.
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2. Host defense of Drosophila and mammals
Drosophila can defend against microorganisms by
producing antimicrobial peptides. A type I trans-
membrane protein, Toll, was found to play a critical
role in this antifungal defense [1]. In addition, 18-
wheeler, which is structurally related to Toll, was
shown to play a critical role in antibacterial defense
[2]. Upon infection, Toll and 18-wheeler induce pro-
duction of antimicrobial peptides such as drosomycin
and attacin, respectively. Recently, sequencing of the
Drosophila genome has revealed the existence of nine
proteins that belong to Toll family [3]. Although the
functions of all family members have not yet been
clari¢ed, it can be assumed that each member is in-
volved in the defensive response against pathogens.
In the mid 1990s, the ¢rst protein that is structur-
ally related to Drosophila Toll was identi¢ed and is
now called as human TLR1 [4,5]. In 1997, Janeway’s
group characterized another mammalian Toll-like
protein (human TLR4) and ¢rst implied its function-
al role in the immune response [6]. To date, ten hu-
man and nine murine transmembrane proteins have
been shown to belong to the mammalian TLR family
[7^11]. Toll and TLR family proteins are character-
ized by the presence of extracellular domains with a
leucine-rich repeat and intracytoplasmic regions
called the Toll/Interleukin-1 receptor (IL-1R) homol-
ogy (TIR) domain, so designated by their similarity
to IL-1R and IL-18R. The TIR domains are critical
to both Drosophila Toll and mammalian TLR signal-
ing, indicating that they share homologous signaling
components. For example, the TLR family can acti-
vate nuclear factor (NF)-UB by inducing degradation
of IUB. Toll can also lead to activation of the NF-UB
family homologue, Dif, by inducing degradation of
the IUB homologue, Cactus.
Thus, the Toll and TLR families are a phylogeneti-
cally conserved system for host defense.
3. How are TLRs involved in host defense?
A prerequisite for e¡ective host defense is the rec-
ognition of pathogens. TLRs are involved in this ¢rst
step. Pathogens possess several components that are
not found in the host, and have been referred to as
pathogen-speci¢c molecular patterns (PAMPs) [12].
Upon infection, macrophages recognize these pat-
terns as nonself through the TLRs. TLR signaling
can stimulate macrophage activation by inducing
production of proin£ammatory cytokines and anti-
microbial small molecules such as nitric oxide. Then,
activated macrophages function to eliminate micro-
organisms during the early phase of infection.
However, activation of the innate immune re-
sponse in peripheral tissues has a limited ability to
eradicate pathogens in mammals. More e¡ective host
defense is achieved with activation of the adaptive
immune response, which mainly takes place in sec-
ondary lymphoid tissues such as the lymph nodes.
Dendritic cells (DCs) play an essential role in the
immune response by communicating between the pe-
ripheral and lymphoid tissues [13,14]. This process
mainly involves immature DCs located in the periph-
eral tissues, and these cells constitute a unique cell
population able to activate na|«ve T cells. In contrast
to macrophages, which mainly function to eradicate
pathogens, DCs are important for sensing the invad-
ing pathogen and for instructing the adaptive im-
mune system which is thereby recruited to ¢ght
against the infection. In order to activate T cells,
DCs need to ¢rst leave the peripheral tissues and
migrate to the lymph nodes [15]. This DC tra⁄cking
is mediated by chemokine receptors that are ex-
pressed on DCs following stimulation of TLRs [16^
18] (Fig. 1). For example, LPS can downregulate
expression of the chemokine receptors such as
CCR5, but can also upregulate CCR7 expression.
Concomitantly, DCs can also produce a variety of
chemokines that recruit natural killer cells and na|«ve
T cells.
TLR signaling stimulates the maturation of DCs,
which migrate to the lymph nodes where they stim-
ulate T cells by presentation of antigen^major histo-
compatibility (MHC) complexes. Antigen presenta-
tion alone can stimulate pathogen-speci¢c T-cell
clones, but is not su⁄cient to trigger e⁄cient T-cell
expansion. Clonal T-cell expansion requires an addi-
tional signal delivered by costimulatory molecules
such as CD80/86. TLR signaling functions to trigger
adaptive immunity by enhancing expression of not
only MHC molecules but also of these costimulatory
molecules in DCs (Fig. 1).
In addition to T-cell expansion, T-cell di¡erentia-
tion is also quite important for the establishment of
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e¡ective adaptive immunity. T cells can di¡erentiate
into two distinct subsets, i.e., TH1 and TH2 [19]. TH1
cells secrete mainly the e¡ector cytokine IFN-Q and
are involved in cellular immunity. TH2 cells produce
the e¡ector cytokines IL-4, IL-10, and IL-13 and are
involved in humoral immunity. This decision to dif-
ferentiate into TH1 or TH2 can be directed by DCs,
depending on the particular DC subset, DC matura-
tion stage, or the DC-to-T cell ratio [20,21]. Bacterial
infection activates DCs via stimulation of the TLRs
and induces mainly TH1-inducing cytokines such as
IL-12. Therefore, TLR-stimulated DCs tend to direct
T-cell di¡erentiation towards the TH1 cell type (Fig.
1). At present it remains unknown whether DCs can
also be activated to instruct TH2 cell di¡erentiation
by stimulation of certain TLRs upon infection with
helminths or certain microbes.
Taken together, these observations show that
TLRs are crucial not only in the early phase of in-
fection, but also in linking innate and adaptive im-
munity throughout the entire course of the host de-
fense response. Their involvement in multiple
immunostimulatory activities de¢ne TLRs as the
general adjuvant receptors in the body.
4. Pathogen recognition by the TLR family
In this section, we describe the relationship be-
tween TLRs and their ligands (Table 1). So far a
number of ligands have been identi¢ed through in
vitro systems or knockout mice. Most of these li-
gands can be classi¢ed as PAMPs, but non-PAMP
as well as PAMP ligands seem to play important
roles in eliciting not only the host defense but also
various in£ammatory processes.
4.1. Lipopolysaccharide (LPS) and TLR4
The best-characterized PAMP is LPS, a major
component of the outer membrane of gram-negative
bacteria (Fig. 2). LPS is composed of polysaccharides
extending outward from the bacterial cell surface and
a lipid portion, lipid A, which is embedded in the cell
Fig. 1. Activation of adaptive immunity through TLRs. First, immature DCs in the peripheral tissues sense invading pathogens.
Pathogens are recognized by TLRs or captured by endocytosis. TLR signaling can lead to DC maturation. Mature DCs exhibit low
expression of CCR5 and high expression of CCR7, which can cooperatively provide DCs with the ability to exit from tissues and mi-
grate into the draining lymphoid tissues. Concomitantly, captured pathogens are processed. Processed products are then presented to
T cells as antigen^MHC complexes. TLR signaling plays critical roles also in clonal T-cell activation by augmenting expression of
MHC molecules and costimulatory molecules. TLRs can also regulate T-cell di¡erentiation status by producing proin£ammatory cyto-
kines such as IL-12. IL-12 can instruct na|«ve T cells to di¡erentiate into TH1 cells. Thus, establishment of adaptive immunity is
greatly in£uenced by TLR-stimulated DCs.
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surface. LPS can provoke a variety of immunostimu-
latory responses, for example production of proin-
£ammatory cytokines such as IL-12 and in£amma-
tory e¡ector substances such as nitric oxide. These
biological activities can be ascribed to the lipid A
portion of LPS. In su⁄cient quantity, LPS can cause
a clinically life-threatening condition called endotox-
in shock. A glycosylphosphatidylinositol (GPI)-an-
choring protein, CD14, was identi¢ed that facilitates
LPS action by binding and retaining LPS on the cell
surface. However, CD14 lacks an intracytoplasmic
region, suggesting that another membrane protein(s)
may be essential for LPS signaling.
In 1998, genetic analysis revealed that TLR4 is a
critical signal transducer for LPS [22,23]. C3H/HeJ
and C57BL/10ScCr are mutant mouse strains that
are defective in their responses to LPS. Both mutants
carry a mutation in the TLR4 gene. The TLR4 gene
isolated from C3H/HeJ mice encodes a histidine res-
idue in place of a well-conserved proline in the intra-
cytoplasmic region. The proline is indeed essential
for TLR4 signaling [24,25]. In addition, the C57BL/
10ScCr strain contains a chromosomal deletion in
the TLR4 genomic locus. The idea that TLR4 is
critical for LPS signaling was further con¢rmed by
generation of TLR4-de¢cient mice [24]. Furthermore,
in humans, TLR4 mutations are associated with im-
paired responsiveness to LPS [26].
Initially, experiments performed using in vitro
overexpression of TLRs indicated that TLR2 is a
receptor for LPS as a result of this. However, this
result was found to be due to some contaminants
which can function as TLR2 agonists [27]. Although
certain species of LPS, derived from Leptospira or
Table 1
TLRs and their ligands
TLRs Origin of ligands Ligands
TLR2 Gram bacteria Lipoproteins [77,78]
Peptidoglycan [30,79]
(TLR2/6 [33] or TLR2/X [35])a
Lipoteichoic acids [79,80]
Staphylococcus Modulin (TLR2/6) [81]
Bacteria Lipopeptides (TLR2/X) [33,35]
Mycoplasma, Mycobacteria, Spirochetes Lipoproteins, lipopeptides [82^85]
Mycoplasma MALP-2 (TLR2/6) [31,35]
Spirochetes Glycolipids [80]
Listeria Heat-killed bacteria [86]
Mycobacteria Lipoarabinomannan [25,87,88]
Porphyromonas, Spirochetes (Leptospira) LPS [28,29]
Yeast Zymosan (TLR2/6) [33,78]
Trypanosoma cruzi GPI anchors [89]
Klebsiella Outer membrane protein A [90]
Neisseria meningitides Soluble factors (TLR1/2) [34]
TLR3 Virus dsRNA [47]
TLR4 Gram3 bacteria LPS [22^24]
Gram bacteria Lipoteichoic acids [30]
Plant Taxol [48]
Respiratory syncytial virus F protein [49]
Host HSP60 [51,52]
Fibronectin EDA domain [56]
TLR5 Bacteria with £agella Flagellin [44]
TLR9 Bacteria Unmethylated CpG DNA [10]
aSome TLR2 ligands are recognized by TLR2-including heterodimers. The identi¢ed dimers are shown in parentheses.
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Porphyromonas, have subsequently been shown to
act through TLR2, they are structurally di¡erent
from the typical Escherichia coli or Salmonella LPS
[28,29]. It is generally accepted that LPS from Gram-
negative bacteria stimulate in£ammatory responses
through TLR4.
4.2. TLR2 recognizes a variety of pathogens
Gram-positive bacteria do not produce LPS, but
still can provoke immune responses similar to those
generated by LPS. The cell wall of Gram-positive
bacteria contains a thick layer of peptidoglycan
(PGN) within which lipoproteins and lipoteichoic
acids are embedded (Fig. 2). Analysis of TLR2-de¢-
cient mice demonstrated clearly that TLR2 is essen-
tial for the response to PGN [30].
Mycoplasma is a pathogen that lacks a cell wall
(Fig. 2), but its cytoplasmic membrane contains var-
ious lipoproteins or lipopeptides that can also cause
in£ammatory responses. One of the Mycoplasma li-
popeptides, the 2 kDa macrophage-activating lipo-
peptide-2 (MALP-2), was shown to utilize TLR2 as
its signal transducer [31]. Furthermore, TLR2 was
found to be critical for responses to a number of
lipoproteins derived from a variety of pathogens (Ta-
ble 1), including lipoarabinomannan, which is a ma-
jor cell wall-associated glycolipid derived from My-
cobacterium tuberculosis (Fig. 2) [32].
How can TLR2 recognize such a wide variety of
PAMPs? One possibility is that TLR2 forms hetero-
dimers with other TLRs. This possibility was dem-
onstrated by an in vitro expression system [33].
Dominant negative forms of either TLR2 or TLR6
were found to inhibit tumor necrosis factor-K expres-
sion normally induced by zymosan, Gram-positive
bacteria, or PGN. Furthermore, coexpression of
TLR2 with TLR6 could confer NF-UB activation
and cytokine production, while cells expressing
TLR2 alone could not. Thus, TLR2 appears to func-
tion in some cases by forming heterodimers with
other TLRs. Because a dominant negative form of
Fig. 2. Schematic representation of PAMPs. Gram-positive bacteria contain a thick layer of PGN in the cell wall. Lipoteichoic acids,
teichoic acids, and lipoproteins are also embedded in this cell wall. Gram-negative bacteria have a thinner layer of PGN in the cell
wall compared to Gram-positive bacteria. The cell wall of Gram-negative bacteria is further typi¢ed by the presence of LPS on the
outer surface. LPS is comprised of an active component, the lipid A portion, and O-polysaccharide (O-antigen). The latter is exposed
outside the cell surface. Porins are involved in forming pores through which small molecules can transverse. Mycoplasma lacks a cell
wall, but lipoproteins and lipopeptides are embedded in its cytoplasmic membrane. Mycobacterium tuberculosis has a characteristic
thick hydrophobic layer containing mycolyl arabinogalactan and trehalose dimycolate, in addition to a cytoplasmic membrane and a
PGN layer. Lipoarabinomannan is a major cell wall-associated glycolipid. Some of these PAMPs show strong immunostimulatory ac-
tivity via TLR family members.
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TLR2, but not of TLR6, can also inhibit responses
to bacterial lipopeptides, it is possible that TLR2 can
also heterodimerize with other TLRs. TLR2 has fur-
ther been shown to form functional heterodimers
with TLR1, required for recognition of certain fac-
tors released by Neisseria meningitidis [34]. Thus,
TLR2 appears to broaden its repertoire of speci¢c-
ities by forming at least two distinct types of func-
tional heterodimers with other TLRs. A similar con-
clusion was reached by in vivo analysis using TLR2-
or TLR6-de¢cient mice [35]. The molecular structure
of MALP-2 is only slightly di¡erent from that of
bacterial lipoprotein, in that the former is diacylated,
while the latter is triacylated at the N-terminal cys-
teine residue. Responses to both PAMPs were abol-
ished in TLR2-de¢cient macrophage, but only the
response to MALP-2 was abolished in TLR6-de¢-
cient macrophage [35]. We assume that TLR2/
TLR6 and an as-yet unde¢ned heterodimer, TLR2/
TLRX, can recognize MALP-2 and bacterial lipo-
peptides, respectively. Thus, TLR2 appears to
achieve its ¢ne speci¢city by pairing with distinct
TLRs.
4.3. CpG DNA and TLR9
In addition to cell wall components, bacterial
DNAs can also function as PAMPs. This was origi-
nally demonstrated by Tokunaga et al. [36]. They
found an immunostimulatory activity in extracts of
bacillus Calmette Guerin (BCG) that could be attrib-
uted to the e¡ects of DNA. The activity was even-
tually shown to require unmethylated CpG motifs,
which are rarely detected in vertebrate DNA. Not
only bacterial DNA, but oligodeoxynucleotides car-
rying the CpG motif can exhibit immunostimulatory
activities on human and murine lymphocytes and
antigen-presenting cells. This stimulation leads to
the production of TH1 cytokines and costimulatory
molecule upregulation. This activity is so potent that
CpG DNA has been utilized as a powerful adjuvant.
CpG DNA-conjugated proteins have been shown to
promote both the antigen presenting activity and
maturation of DCs, thereby enhancing antigen-spe-
ci¢c TH1 responses [37].
Analysis of TLR9-de¢cient mice has further clari-
¢ed the idea that the TLR family is involved in rec-
ognizing this bacterial DNA as PAMP. All CpG
DNA-induced e¡ects, including cytokine production,
B-cell proliferation, DC maturation, and induction
of systemic shock were completely abolished in
TLR9-de¢cient cells and mice [10]. In humans,
TLR9 is selectively expressed on plasmacytoid DCs,
but not on monocyte-derived DCs [38^40]. CpG
DNA can induce cytokine production from the for-
mer, but not from the latter, consistent with the fact
that response to CpG DNA is dependent on TLR9
expression. Furthermore, human and mouse TLR9
confer the responsiveness via species-speci¢c CpG
motif recognition [38]. These results demonstrate
that TLR9 is a critical signal transducer for CpG
DNA.
Independently, Chu et al. have shown that the
DNA-dependent protein kinase (DNA-PKc) is essen-
tial for the e¡ects of immunostimulatory DNAs [41].
So far there is no evidence connecting DNA-PKc
and TLR9, and further studies will be necessary to
clarify whether DNA-PKc and TLR9 act sequen-
tially or in parallel.
4.4. Flagellin and TLR5
Most bacilli including Salmonella possess a soluble
factor, £agellin, which is the monomeric subunit of
£agella. Flagellin shows potent proin£ammatory ac-
tivity by inducing IUB degradation, NF-UB activa-
tion, and expression of IL-8 and inducible NO syn-
thase in intestinal epithelial cells [42,43]. Therefore,
£agellin can be also regarded as another PAMPs. In
vitro expression of TLR5 can confer £agellin respon-
siveness on Chinese hamster ovary (CHO) cells, in-
dicating that £agellins exert its activity through
TLR5 [44]. Furthermore, TLR5 is exclusively ex-
pressed on the basolateral surface of intestinal epi-
thelia [45], which is consistent with the fact that £ag-
ellin can show proin£ammatory activity through the
basolateral, not through the apical, surface [46].
However, TLR5-de¢cient mice should be analyzed
to con¢rm the conclusion that TLR5 is a critical
signal transducer for £agellin.
4.5. Double-stranded RNA (dsRNA) and TLR3
Viral replication within infected cells results in
generation of dsRNA that can provoke antiviral de-
fense. Because host cells do not produce dsRNA,
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dsRNA can also be considered as PAMPs. TLR3-
de¢cient mice showed decreased responses to viral
RNA mimic, polyinosine-polycytidylic acid
(poly(I:C)), suggesting that TLR3 is involved in rec-
ognition of dsRNA [47]. TLR3-de¢cient mice are
powerful tools to clarify the roles of TLR3 in viral
infection.
4.6. Non-PAMP ligands for TLR4
TLR4 can recognize not only LPS but also other
substances distantly related to LPS. For example,
TLR4 can recognize plant products. A diterpene
from plant extract, taxol, is widely used as an anti-
cancer drug, but exhibits immunostimulatory activity
in macrophages. This LPS-like activity depends on
TLR4 signaling [48]. It is also reported that TLR4
is involved in viral recognition [49]. F protein from
respiratory syncytial virus (RSV) can induce proin-
£ammatory cytokines via its stimulation of TLR4
and CD14 [49]. They further showed that C57BL/
10ScCr were impaired in their ability to eliminate
RSV, arguing that TLR4 is essential for antiviral
defense. However, the mutant mice possess mutation
not only on TLR4 but also on IL-12RL2 genes [50],
which may possibly be responsible for defective im-
munity against RSV. Therefore, further study is nec-
essary to conclude that TLR4 is critical for antiviral
immunity.
Intriguingly, the TLR family is critical for recog-
nizing certain endogenous molecules as well as
PAMPs. For example, heat sock protein 60
(HSP60) has been shown to provoke an in£amma-
tory response in normal mice, but not in C3H/HeJ
mice, suggesting that this activity is mediated by
TLR4 [51]. Furthermore, Vabulas et al. found that
both human and chlamydial HSP60 can activate NF-
UB and mitogen-activated protein kinases (MAPKs)
through TLR2 or TLR4 [52]. HSPs are released from
necrotic cells in certain pathological conditions, such
as injury, and induce DC maturation by activating
NF-UB [53]. Such immune activation may provide a
molecular basis for the danger theory of immune
activation proposed by Matzinger [54]. According
to this theory, the immune system does not discrim-
inate between self and nonself per se, as has been
long believed, but rather responds to antigens that
are associated with danger signals released from
damaged or stressed cells. CD91, which is not a
TLR family member, has been identi¢ed as a recep-
tor for HSPs [55]. It is most likely that CD91 is
involved in uptake of HSPs, after which TLR deliv-
ers a signal to trigger in£ammatory processes. Fur-
ther studies are necessary to clarify how TLR family
and CD91 coordinately function as the receptors for
substances from damaged cells.
During in£ammation or tissue injury, extracellular
matrix components such as ¢bronectin or collagen,
are degraded by proteases, thus accelerating the in-
£ammatory cascades. Degraded fragments of ¢bro-
nectin have been shown to exert their proin£amma-
tory activity through TLR4 [56]. Thus, TLR4
appears to be uniquely involved in the recognition
of host-derived in£ammatory products, leading to
the establishment of in£ammatory responses.
5. TLR family signaling pathways
TLRs activate signal transduction cascades leading
to expression of immune response genes following
recognition of their respective ligands. The mecha-
nism of TLR signaling is quite similar to that of
the IL-1R family, because both receptor families pos-
sess TIR domains (see above). MyD88, a cytoplasmic
adapter protein, associates with all members of the
IL-1R and TLR families [57^60]. Activation of NF-
UB and MAPK cascades involves a signaling com-
plex that contains MyD88, IL-1R-associated kinase
(IRAK) and tumor necrosis factor receptor-associ-
ated factor 6 (TRAF6) [58,61]. MyD88-de¢cient cells
were found to lack activation of NF-UB and MAPKs
and any biological responses following stimulation
by IL-1 or IL-18, indicating that MyD88 is an essen-
tial adapter for signaling by these cytokines [62].
Furthermore, NF-UB activation was abrogated in
MyD88-de¢cient cells stimulated with ligands for
TLR2 and TLR9 (Fig. 3), indicating that TLR
family signaling requires MyD88. However, NF-UB
and MAPK activation in response to LPS was re-
tained in MyD88-de¢cient cells, although with de-
layed kinetics, (Fig. 3 and [63]). Therefore, among
IL-1R and TLR family members, TLR4 is unique
in the respect that its signaling can lead to NF-UB
and MAPK activation in a MyD88-independent
manner.
BBAMCR 14831 21-2-02
T. Kaisho, S. Akira / Biochimica et Biophysica Acta 1589 (2002) 1^13 7
6. Biological signi¢cance of the MyD88-independent
pathway
Curiously, while cytokine induction in response to
LPS was abolished in MyD88-de¢cient macrophages,
activation of NF-UB was retained (Fig. 3). In addi-
tion to cytokine induction, other LPS-induced e¡ects
including NO production, B-cell blast formation and
endotoxin shock were also fully abolished in MyD88-
de¢cient mice [63]. Therefore, the question is whether
stimulation via the MyD88-independent pathway has
any biological consequence.
As described above, DCs express a vast repertoire
of TLRs on their surface [64] and undergo matura-
tion in response to various infectious stimuli, includ-
ing LPS and CpG DNA. This process can be dupli-
cated in vitro by culturing bone marrow (BM) cells
with GM-CSF. BM DCs were generated from wild-
type and various mutant mice and analyzed for their
responses to LPS [65]. Cytokine production in re-
sponse to LPS was abolished in both TLR4- and
MyD88-de¢cient BM DCs, consistent with the pre-
vious results from macrophages [63]. However, up-
regulation of costimulatory molecules was retained in
MyD88-, but not TLR4-, de¢cient BM DCs. This
upregulation has functional consequences, since
LPS could still enhance the allostimulatory activity
of MyD88-de¢cient BM DCs. Furthermore, LPS-in-
duced, MyD88-independent upregulation of costimu-
latory molecules was detected not only in vitro BM
DCs, but also in vivo splenic CD11c DCs [65].
Thus, two major biological e¡ects provoked by
LPS, i.e., cytokine production and costimulatory
molecule upregulation, di¡er in their requirement
for MyD88.
7. Molecular basis for the MyD88-independent
pathway
At present, the molecular mechanism underlying
the MyD88-independent pathway is unclear. C3H/
HeJ-derived BM DCs showed impairment of both
cytokine and costimulatory molecule induction in re-
sponse to LPS [65]. This indicates that the conserved
proline residue in TLR4 is critical for both MyD88-
dependent and -independent pathways, and that both
pathways presumably originate from the intracyto-
plasmic region of TLR4. IRAK appears to be an
integral component of the MyD88-dependent path-
way, as IRAK activation is abolished in MyD88-de-
¢cient DCs. It is noteworthy that IRAK-de¢cient
Fig. 3. LPS can induce NF-UB activity, but cannot stimulate cytokine production in MyD88-de¢cient macrophages. Macrophages
from wild-type and mutant mice were stimulated with the ligands for TLR2, TLR4, and TLR9. In the cases of TLR2 and TLR9, li-
gand-induced NF-UB activity was completely dependent on MyD88 and the cognate receptor. In the case of TLR4, activation oc-
curred in the absence of MyD88, suggesting the existence of a MyD88-independent pathway downstream of TLR4. However, cytokine
induction in response to all these TLR ligands was completely abolished in MyD88-de¢cient cells.
BBAMCR 14831 21-2-02
T. Kaisho, S. Akira / Biochimica et Biophysica Acta 1589 (2002) 1^138
macrophages showed delayed activation of NF-UB
and MAPK cascades, similar to what is observed
in MyD88-de¢cient macrophages [66]. Furthermore,
in response to LPS, TRAF6-de¢cient embryonic ¢-
broblasts exhibited impaired, but still detectable lev-
els of NF-UB activation with delayed kinetics [67].
Taken together, these results suggest that the
MyD88-independent pathway bifurcates at the intra-
cytoplasmic region of TLR4, but converges again at
or just downstream of TRAF6 (Fig. 4).
Subtractive hybridization analysis revealed that
several interferon (IFN)-inducible genes, including a
CXC chemokine, IFN-inducible protein 10 (IP-10)
and IFN-regulated gene-1 (IRG-1), were induced in
MyD88-de¢cient macrophages in response to LPS
[67]. IP-10 gene induction requires IFN regulatory
factor 3 (IRF-3) [68], and nuclear translocation of
IRF-3 in response to LPS is detected in MyD88-de-
¢cient cells [67]. Therefore, it is likely that IRF-3
activation contributes to the MyD88-independent
pathway. At present it is not known how IRF3 is
activated downstream of TLR4.
Furthermore, in response to LPS, MyD88-de¢cient
liver macrophages, i.e., Kup¡er cells, can secrete ac-
tive IL-18 in a caspase 1-dependent manner [69],
suggesting the involvement of other factors in the
MyD88-independent pathway.
It is quite intriguing to compare TLR4 with other
TLR signaling. For example, TLR9 signaling exhib-
its similar e¡ects to TLR4 signaling, i.e., cytokine
induction and costimulatory molecule upregulation.
However, in contrast to TLR4, all the e¡ects induced
by TLR9 signaling are dependent on MyD88 [65].
The results indicate that TLR4 and TLR9 can acti-
vate distinct signaling mechanisms, even while lead-
ing to similar biological e¡ects. Thus it is quite im-
portant to elucidate di¡erences among individual
TLR signaling mechanisms.
Recently, two independent groups identi¢ed a nov-
el adapter protein for TLR4, called as TIR domain-
containing adapter protein (TIRAP) or MyD88-
adapter-like (Mal) [70,71]. TIRAP/Mal associates
with TLR4, but not with TLR9 and is critical for
LPS-induced DC maturation [70]. TIRAP/Mal can
form homodimers or heterodimers with MyD88
and also associate with IRAK-2, thereby connecting
with NF-UB activation [71]. However, it still remains
unknown how or whether TIRAP/Mal is involved in
Fig. 4. TLR4 and TLR9 can exert biologically similar e¡ects through distinct signaling pathways. Both TLR4 and TLR9 can activate
signaling pathways emanating from MyD88. This pathway sequentially activates IRAK and TRAF6 and leads to activation of NF-UB
and MAPKs (not shown). Notably, TLR4, but not TLR9, can activate NF-UB and MAPKs in a MyD88-independent and TIRAP/
Mal-dependent manner. Cytokine induction in response to both TLR4 and TLR9 ligands is completely dependent on MyD88. Both
TLR4 and TLR9 signaling can induce upregulation of costimulatory molecules and T-cell stimulatory activity. However, these e¡ects
di¡er in their requirement for MyD88; that is, TLR4-induced biological e¡ects are MyD88-independent whereas TLR9-induced ones
are dependent on MyD88.
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IRF3 or caspase 1 activation. Furthermore, in vivo
roles of TIRAP/Mal should also be clari¢ed.
8. How TLRs recognize their ligands
A⁄nity between TLRs and their ligands seems
lower than that between cytokines and their recep-
tors. In spite of low a⁄nity, TLRs themselves seem
to recognize their ligands speci¢cally. This has been
demonstrated by analyzing species-speci¢c responses
to TLR ligands. Human and rodent cells di¡eren-
tially respond to LPS or lipid A analogues. These
responses can be reconstituted in LPS-unresponsive
cells by overexpressing human or rodent TLR4s
[72,73]. In addition, the optimal CpG motif for acti-
vation di¡ers between human and mice. This species-
speci¢c CpG motif recognition was also found to be
mediated by TLR9 [38]. Furthermore, TLR9 and
CpG DNA colocalize in the same endocytic vesicles
[74]. Thus, these studies strongly suggest that at least
TLR4 and TLR9 in TLR family members can di-
rectly recognize their ligands.
TLRs recognize a variety of ligands. For example,
TLR4 recognizes lipids (LPS), proteins (HSP60, F
protein), and diterpene (Taxol). TLR2 also recog-
nizes a variety of products from various microorgan-
isms. This might be partly due to their low a⁄nity
interactions. Meanwhile, as described above, TLR2
seems to discriminate ¢ne molecular patterns de-
pending on the heterodimerizing receptor partner.
Thus, it would be quite intriguing to clarify how
TLRs recognize their ligands. Crystallization experi-
ments should contribute to the resolution of this is-
sue.
Microbial recognition by TLRs is not determined
by TLRs alone. A small secreted molecule, MD-2,
was shown to associate with the extracellular domain
of TLR4 and facilitate the interaction of TLR4 with
ligands such as LPS and taxol [48,75]. Furthermore,
a point mutation in the gene encoding MD-2 can
lead to LPS-unresponsiveness, although this muta-
tion does not abolish the ability of MD-2 to interact
with TLR4 [76]. Resolving how MD-2 contributes to
formation of the LPS receptor complex is another
important issue for the future.
9. Concluding remarks
Antibiotics have proven to be powerful tools in the
control of infectious disease. However, the use of
even very powerful antibiotics has been accompanied
by the emergence of pathogens with multidrug resis-
tance. Therefore, the development of non-antibiotic
agents, including vaccines, are expected to contribute
to the ¢ght against microbial pathogens. Formerly,
vaccines employed live attenuated pathogens, whole
inactivated organisms, and inactivated toxins, but
these agents also produced undesirable side e¡ects.
Recently recombinant proteins and synthetic pep-
tides have emerged as alternative approaches to vac-
cine development. However, because of their poor
immunogenicity, these molecules typically must be
coadministered with immunostimulatory adjuvants
in order to evoke strong immune responses. The mo-
lecular mechanisms underlying adjuvant activity was
poorly understood for a long time, but the discovery
and functional analyses of TLRs have revealed that
TLRs can function as adjuvant receptors. Therefore,
we may be able to obtain novel types of immuno-
modulatory reagents by modulating the TLR system.
For example, reagents that enhance TLR signaling
pathways can be powerful adjuvants for ¢ghting
against pathogens or cancers, perhaps with fewer
side e¡ects. Furthermore, because the TLR family
may be involved in the pathogenesis of in£ammation
via recognition of host products, reagents that inhibit
TLR action may work as anti-in£ammatory drugs,
and possibly also as agents to treat autoimmune dis-
eases. Thus, our increasing understanding of the
TLR system could be the basis for treating a variety
of pathological conditions.
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